Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02292186 · ClinicalTrials.gov registry record · Phase 2
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT02292186 is a Phase 2 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT02292186, a Phase 2 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.
Interventions
- DRUG Revusiran (ALN-TTRSC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-10 |
| Est. Completion | 2017-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02292186
The ClinicalTrials.gov registry entry for NCT02292186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Revusiran (ALN-TTRSC) is the first listed.
NCT02292186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02292186 about?
NCT02292186 is a clinical study titled "A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis". The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.
What is the current status of trial NCT02292186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2014-10. Estimated completion is 2017-02-22.
What interventions are being tested in trial NCT02292186?
The interventions under investigation include: Revusiran (ALN-TTRSC) (DRUG).
Who is sponsoring clinical trial NCT02292186?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.